通过生物信息学分析和门德尔随机化研究,探索eurtgliflozin和癌之间的潜在机制
Bo Xu1,2,3,4,5,6, Peng Xiang1,2,3,4,6, Xiongwen Yang5
1The First Affiliated Hospital, Hunan Provincial Clinical Medical Research Center for Drug Evaluation of Major Chronic Diseases, Hengyang Medical School, University of South China, Hengyang Hunan, China.
International journal of surgery (London, England)
|February 18, 2026
概括
埃尔图格利弗洛辛可能通过向ESR2.2,增加癌风险. -葡萄糖共运输体2 (SGLT2) 抑制也与癌有关,需要进一步研究.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
背景情况:
- 关于-葡萄糖共运输体2 (SGLT2) 抑制剂和癌风险存在争议.
- 最近的研究表明,埃尔格利弗洛辛可能会提高整体和癌发病率.
研究的目的:
- 通过使用多维数据,研究潜在的机制,将eurgliflozin与癌联系起来.
- 探索SGLT2抑制与细胞癌 (RCC) 之间的关联.
主要方法:
- 网络毒理学确定了埃尔格利弗洛辛和清细胞脏细胞癌 (ccRCC) 之间的核心目标.
- 在TCGA数据库分析和SLC5A2分析中,发现了特征基因.
- 两个样本的孟德尔随机化 (MR) 评估了特征基因,SGLT2抑制和RCC/ccRCC之间的关联.
主要成果:
- 确定了15个核心目标;SRC和ESR2被选为特征基因.
- ESR2显示了与ccRCC风险增加的潜在关联 (P=0.03).
- 在英国生物库数据中,SGLT2抑制与较高的RCC风险 (OR3.05,P=0.04) 和ccRCC风险相关 (OR 83.70,P<0.01). 埃尔图格利弗洛辛根据ESR2.2采取行动.
结论:
- 埃尔图格利弗洛辛可能通过向ESR2.2来影响癌.
- 抑制SGLT2可能会导致癌的发展.
- 需要进一步的研究来阐明这些关系.
相关概念视频
01:28Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
256
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
256
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
24
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
24